Literature DB >> 17700713

Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats.

W Dimpfel1.   

Abstract

BACKGROUND AND
PURPOSE: Drug administration modifies the balance of neurotransmitter-controlled ion channel activity and consequently the firing pattern of local neuronal populations and intracerebral field potentials. Fast Fourier Transformation of these field potentials provides an electropharmacogram depicting drug-induced changes within defined frequency ranges. The present investigation was undertaken to investigate the difference between atypical and typical antipsychotic drugs. EXPERIMENTAL APPROACH: Adult Fisher rats were implanted with 4 bipolar concentric steel electrodes using a stereotactic surgical procedure. Field potentials from four selected brain areas in freely moving rats were used to analyse the frequency content of the electropharmacogram after administration of 4 clinically used atypical antipsychotic drugs. KEY
RESULTS: Atypical antipsychotics exerted effects similar to those reported for typical antipsychotics, on the electropharmacogram during the first hour after administration, whereas clear differences emerged during the second and third hour after dosing. During the latter period, only atypical antipsychotic drugs produced a statistically significant decrease in alpha1 and beta1 spectral power, especially within the striatum, somewhat less in the cortex. CONCLUSIONS AND IMPLICATIONS: Previous studies have attributed alpha1 frequency changes to the influence of 5-hydroxytryptamine (5-HT) and the present data are consistent with additional binding of atypical drugs to 5-HT receptors. This implies that a change in the balance between dopaminergic and 5-hydroxytryptaminergic neurotransmission (activation of both) is likely to underlie the relative lack of extrapyramidal side effects characteristic of atypical antipsychotics and also for their higher efficacy in the treatment of mood and cognition deficits in schizophrenics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700713      PMCID: PMC2050823          DOI: 10.1038/sj.bjp.0707427

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

Authors:  S Kapur; P Seeman
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment.

Authors:  Brian Dean; Geoffrey Pavey; David Thomas; Elizabeth Scarr
Journal:  Schizophr Res       Date:  2006-08-17       Impact factor: 4.939

3.  Dopamine and serotonin receptor binding and antipsychotic efficacy.

Authors:  Neil M Richtand; Jeffrey A Welge; Aaron D Logue; Paul E Keck; Stephen M Strakowski; Robert K McNamara
Journal:  Neuropsychopharmacology       Date:  2007-01-24       Impact factor: 7.853

4.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Authors:  H Y Meltzer; S Matsubara; J C Lee
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

Review 5.  Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.

Authors:  Darakhshan Jabeen Haleem
Journal:  J Coll Physicians Surg Pak       Date:  2006-08       Impact factor: 0.711

6.  Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG).

Authors:  Wilfried Dimpfel
Journal:  Eur Neuropsychopharmacol       Date:  2005-07-11       Impact factor: 4.600

7.  Quantitative EEG and BPRS data following Haldol-Decanoate administration in schizophrenics.

Authors:  R Schellenberg; W Milch; A Schwarz; F Schober; W Dimpfel
Journal:  Int Clin Psychopharmacol       Date:  1994       Impact factor: 1.659

8.  A pharmaco-EEG study on antipsychotic drugs in healthy volunteers.

Authors:  Masafumi Yoshimura; Thomas Koenig; Satoshi Irisawa; Toshiaki Isotani; Keizo Yamada; Mitsuru Kikuchi; Gaku Okugawa; Takami Yagyu; Toshihiko Kinoshita; Werner Strik; Thomas Dierks
Journal:  Psychopharmacology (Berl)       Date:  2007-02-27       Impact factor: 4.530

9.  Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers.

Authors:  A M Hughes; P Lynch; J Rhodes; C M Ervine; R A Yates
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

10.  Multiunit activity from the A9 and A10 areas in rats following chronic treatment with different neuroleptic drugs.

Authors:  A Todorova; W Dimpfel
Journal:  Eur Neuropsychopharmacol       Date:  1994-12       Impact factor: 4.600

View more
  5 in total

1.  Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships.

Authors:  Wojciech Danysz; Gunnar Flik; Andrew McCreary; Carsten Tober; Wilfried Dimpfel; Jean C Bizot; Richard Kostrzewa; Russell W Brown; Claudia C Jatzke; Sergio Greco; Ann-Kristin Jenssen; Christopher G Parsons
Journal:  J Neural Transm (Vienna)       Date:  2015-03-22       Impact factor: 3.575

2.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Authors:  Robert W Gould; Michael T Nedelcovych; Xuewen Gong; Erica Tsai; Michael Bubser; Thomas M Bridges; Michael R Wood; Mark E Duggan; Nicholas J Brandon; John Dunlop; Michael W Wood; Magnus Ivarsson; Meredith J Noetzel; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2015-11-23       Impact factor: 5.250

3.  Early effect of NEURAPAS® balance on current source density (CSD) of human EEG.

Authors:  Wilfried Dimpfel; Klaus Koch; Gabriele Weiss
Journal:  BMC Psychiatry       Date:  2011-08-02       Impact factor: 3.630

4.  Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.

Authors:  Abdallah Ahnaou; Ria Biermans; Wilhelmus H Drinkenburg
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

5.  Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity.

Authors:  A Ahnaou; H Huysmans; T Van de Casteele; W H I M Drinkenburg
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.